Research ExplorerPublicationsPTEN deletions are related to disease progression and unfavo...

PTEN deletions are related to disease progression and unfavourable prognosis in early bladder cancer

Standard

PTEN deletions are related to disease progression and unfavourable prognosis in early bladder cancer. / Cordes, Inga; Kluth, Martina; Zygis, Dominika; Rink, Michael; Chun, Felix; Eichelberg, Christian; Dahlem, Roland; Fisch, Margit; Höppner, Wolfgang; Wagner, Walter; Doh, Ousman; Terracciano, Luigi; Simon, Ronald; Wilczak, Waldemar; Sauter, Guido; Minner, Sarah.

In: HISTOPATHOLOGY, Vol. 63, No. 5, 01.11.2013, p. 670-7.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Cordes, I, Kluth, M, Zygis, D, Rink, M, Chun, F, Eichelberg, C, Dahlem, R, Fisch, M, Höppner, W, Wagner, W, Doh, O, Terracciano, L, Simon, R, Wilczak, W, Sauter, G & Minner, S 2013, 'PTEN deletions are related to disease progression and unfavourable prognosis in early bladder cancer', HISTOPATHOLOGY, vol. 63, no. 5, pp. 670-7. https://doi.org/10.1111/his.12209

APA

Cordes, I., Kluth, M., Zygis, D., Rink, M., Chun, F., Eichelberg, C., Dahlem, R., Fisch, M., Höppner, W., Wagner, W., Doh, O., Terracciano, L., Simon, R., Wilczak, W., Sauter, G., & Minner, S. (2013). PTEN deletions are related to disease progression and unfavourable prognosis in early bladder cancer. HISTOPATHOLOGY, 63(5), 670-7. https://doi.org/10.1111/his.12209

Vancouver

Cordes I, Kluth M, Zygis D, Rink M, Chun F, Eichelberg C et al. PTEN deletions are related to disease progression and unfavourable prognosis in early bladder cancer. HISTOPATHOLOGY. 2013 Nov 1;63(5):670-7. https://doi.org/10.1111/his.12209

Bibtex

@article{8ba21819c61d47f6b6430099f01c8437,
title = "PTEN deletions are related to disease progression and unfavourable prognosis in early bladder cancer",
abstract = "AIMS: This study aimed to determine the prevalence and clinical significance of deletions of the tumour suppressor gene PTEN in bladder cancer.METHODS AND RESULTS: A tissue microarray with 686 bladder cancers was analysed for PTEN deletions by fluorescence in-situ hybridization. PTEN mutations were analysed in nine tumours with heterozygous PTEN deletion. Heterozygous PTEN deletions were present in 16.5% of tumours and were associated with grade (P = 0.0024) and p53 status (P = 0.0141), but not linked to stage (P = 0.0965). PTEN deletions were seen in 5.8% of pTaG1, 10.9% of pTaG2, 29.0% of pTaG3, 16.7% of pT1G2, 22.2% of pT1G3, 17.7% of pT2-4G2 and 20.9% of pT2-4G3 tumours (P = 0.0235). PTEN deletions were associated significantly with recurrences in pTa tumours (P = 0.0173), progression in pT1 tumours (P = 0.0016), but not with overall or cancer-specific survival in pT2 tumours. Multivariate analyses including grade and PTEN deletions revealed that PTEN deletions but not grade were associated independently with recurrence in pTa tumours (P = 0.0377) and progression in pT1 tumours (P = 0.0030). No inactivating PTEN mutations were found.CONCLUSIONS: PTEN is linked to aggressive tumour phenotype and to unfavourable outcome in early bladder cancer. Heterozygous PTEN loss, i.e. reduced PTEN gene dosage, might be sufficient to cause aggressive tumour behaviour in bladder cancer cells.",
keywords = "Adult, Aged, Aged, 80 and over, Disease Progression, Female, Gene Deletion, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, PTEN Phosphohydrolase, Prognosis, Urinary Bladder Neoplasms",
author = "Inga Cordes and Martina Kluth and Dominika Zygis and Michael Rink and Felix Chun and Christian Eichelberg and Roland Dahlem and Margit Fisch and Wolfgang H{\"o}ppner and Walter Wagner and Ousman Doh and Luigi Terracciano and Ronald Simon and Waldemar Wilczak and Guido Sauter and Sarah Minner",
note = "{\textcopyright} 2013 John Wiley & Sons Ltd.",
year = "2013",
month = nov,
day = "1",
doi = "10.1111/his.12209",
language = "English",
volume = "63",
pages = "670--7",
journal = "HISTOPATHOLOGY",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "5",

}

RIS

TY - JOUR

T1 - PTEN deletions are related to disease progression and unfavourable prognosis in early bladder cancer

AU - Cordes, Inga

AU - Kluth, Martina

AU - Zygis, Dominika

AU - Rink, Michael

AU - Chun, Felix

AU - Eichelberg, Christian

AU - Dahlem, Roland

AU - Fisch, Margit

AU - Höppner, Wolfgang

AU - Wagner, Walter

AU - Doh, Ousman

AU - Terracciano, Luigi

AU - Simon, Ronald

AU - Wilczak, Waldemar

AU - Sauter, Guido

AU - Minner, Sarah

N1 - © 2013 John Wiley & Sons Ltd.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - AIMS: This study aimed to determine the prevalence and clinical significance of deletions of the tumour suppressor gene PTEN in bladder cancer.METHODS AND RESULTS: A tissue microarray with 686 bladder cancers was analysed for PTEN deletions by fluorescence in-situ hybridization. PTEN mutations were analysed in nine tumours with heterozygous PTEN deletion. Heterozygous PTEN deletions were present in 16.5% of tumours and were associated with grade (P = 0.0024) and p53 status (P = 0.0141), but not linked to stage (P = 0.0965). PTEN deletions were seen in 5.8% of pTaG1, 10.9% of pTaG2, 29.0% of pTaG3, 16.7% of pT1G2, 22.2% of pT1G3, 17.7% of pT2-4G2 and 20.9% of pT2-4G3 tumours (P = 0.0235). PTEN deletions were associated significantly with recurrences in pTa tumours (P = 0.0173), progression in pT1 tumours (P = 0.0016), but not with overall or cancer-specific survival in pT2 tumours. Multivariate analyses including grade and PTEN deletions revealed that PTEN deletions but not grade were associated independently with recurrence in pTa tumours (P = 0.0377) and progression in pT1 tumours (P = 0.0030). No inactivating PTEN mutations were found.CONCLUSIONS: PTEN is linked to aggressive tumour phenotype and to unfavourable outcome in early bladder cancer. Heterozygous PTEN loss, i.e. reduced PTEN gene dosage, might be sufficient to cause aggressive tumour behaviour in bladder cancer cells.

AB - AIMS: This study aimed to determine the prevalence and clinical significance of deletions of the tumour suppressor gene PTEN in bladder cancer.METHODS AND RESULTS: A tissue microarray with 686 bladder cancers was analysed for PTEN deletions by fluorescence in-situ hybridization. PTEN mutations were analysed in nine tumours with heterozygous PTEN deletion. Heterozygous PTEN deletions were present in 16.5% of tumours and were associated with grade (P = 0.0024) and p53 status (P = 0.0141), but not linked to stage (P = 0.0965). PTEN deletions were seen in 5.8% of pTaG1, 10.9% of pTaG2, 29.0% of pTaG3, 16.7% of pT1G2, 22.2% of pT1G3, 17.7% of pT2-4G2 and 20.9% of pT2-4G3 tumours (P = 0.0235). PTEN deletions were associated significantly with recurrences in pTa tumours (P = 0.0173), progression in pT1 tumours (P = 0.0016), but not with overall or cancer-specific survival in pT2 tumours. Multivariate analyses including grade and PTEN deletions revealed that PTEN deletions but not grade were associated independently with recurrence in pTa tumours (P = 0.0377) and progression in pT1 tumours (P = 0.0030). No inactivating PTEN mutations were found.CONCLUSIONS: PTEN is linked to aggressive tumour phenotype and to unfavourable outcome in early bladder cancer. Heterozygous PTEN loss, i.e. reduced PTEN gene dosage, might be sufficient to cause aggressive tumour behaviour in bladder cancer cells.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Disease Progression

KW - Female

KW - Gene Deletion

KW - Humans

KW - Male

KW - Middle Aged

KW - Neoplasm Recurrence, Local

KW - PTEN Phosphohydrolase

KW - Prognosis

KW - Urinary Bladder Neoplasms

U2 - 10.1111/his.12209

DO - 10.1111/his.12209

M3 - SCORING: Journal article

C2 - 24004025

VL - 63

SP - 670

EP - 677

JO - HISTOPATHOLOGY

JF - HISTOPATHOLOGY

SN - 0309-0167

IS - 5

ER -